are to respond, including the use of appropriate automated electronic, mechanical, or other technological collection techniques or other forms of information technology.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Regulatory Affairs, New Executive Office Building, Room 10235, Washington, DC 20503. Attention: Desk Officer for NIH. To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact: Dr. Nancy Breen, Ph.D., Project Officer, Applied Research Program, Division of Cancer Control and Population Sciences NCI, NIH, EPN 4005, 6130 Executive Boulevard MSC 7344. Bethesda, Maryland 20852–7344, or call the non-toll-free number 301–955–8500 or E-mail your request, including your address to breen@mail.nih.gov.

Comments Due Date: Comments regarding this information collection are best assured of having their full effect if received within 30 days of the date of this publication.


Rachelle Ragland-Greene,
NCI Project Clearance Liaison, National Institutes of Health.

[FR Doc. 07–406 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Call for Nominations for the National Cancer Institute Director’s Consumer Liaison Group

The National Cancer Institute (NCI) of the Federal Government’s primary agency for cancer research, is seeking nominations for four (4) new members of the NCI Director’s Consumer Liaison Group (DCLG) which will be appointed in July, 2007. The DCLG helps NCI to identify appropriate advocates to serve on its program and policy advisory committees.

The National Cancer Institute (NCI) formed the NCI Director’s Consumer Liaison Group (DCLG) in 1998 to advise and make recommendations to the NCI Director, from the perspective and viewpoint of cancer consumer advocates, on a wide variety of issues, programs, and research priorities. The DCLG gives cancer advocates a channel to voice their views and concerns. The DCLG is a 16-member chartered federal advisory committee that works with NCI to ensure that those who experience the burden of cancer also help to shape the course of the NCI’s research to eradicate it. Specifically the DCLG members:

- Help develop and establish processes, mechanisms and criteria for identifying appropriate consumer advocates to serve on a variety of program and policy advisory committees responsible for advancing the mission of the NCI.
- Serve as a primary forum for discussion issues and concerns and exchanging viewpoints that are important to the broad development of the NCI programming and research priorities.
- Establish and maintain strong collaborations between the NCI and the cancer advocacy community to reach common goals.

Eligibility Requirements: NCI looks for strong, highly qualified candidates who fulfill the following eligibility criteria:

• Demonstrate involvement in the cancer experience as a cancer survivor, a caregiver to someone who has cancer, or as a professional or volunteer who works with cancer survivors, patients, or caregivers;
• Have a constituency with which she/he regularly communicates on cancer issues and with which she/he is able to serve as a conduit for information, both to and from NCI.

Nominees who meet the minimum eligibility requirements will be evaluated further based on the following qualities:

• Cancer advocacy experience; ability to represent all cancer survivors;
• Possession of strong leadership, communication, and collaboration skills;
• Ability to advise on broad cross cutting cancer issues;
• Ability to facilitate dialogue between NCI and the cancer advocacy community.

DCLG members must be committed to participating in all activities of the DCLG which includes at least five meetings a year in Bethesda, MD.

Characteristics of the DCLG. In addition to the criteria for individual candidates, the following characteristics of the DCLG as a group are balanced to ensure that it reflects the breadth and diversity of the consumer advocacy community:

• Racial and ethnic balance
• A broad mix of cancer sites
• Expertise with advocacy organizations (local, regional, or national)
• Geographical diversity
• Gender
• Age diversity

Selection Process. A call for nominations is disseminated annually to a broad range of groups, including local, regional and national organizations, to encourage nominations of candidates reflecting the diversity sought for the DCLG. Individuals may nominate themselves. All nominees are screened for eligibility, and then evaluated according to the criteria. A list of highly qualified candidates who reflect balance and diversity of representation is forwarded to the Director, NCI who selects the DCLG members. The original members of the DCLG endorsed this process and the criteria developed to evaluate the applications of potential DCLG members, and this process is used to select future members.

To receive a nomination package for the DCLG, send your name, advocacy/voluntary organization affiliation (if any), address, phone number and E-mail information to: Palladian Partners, Inc., Attn: DCLG 2007 Selection Process, 1010 Wayne Avenue, Suite 1200, Silver Spring, MD 20910. Phone: (301) 650–8660, Fax: (301) 650–8676.

Nominations must be postmarked by March 30, 2007.


Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy, National Institutes of Health.

[FR Doc. 07–400 Filed 1–30–07; 8:45 am]
BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the National Cancer Institute Special Emphasis Panel, February 27, 2007, 12 p.m. to February 27, 2007, 4 p.m., National Institutes of Health, 6130 Executive Blvd., Rockville, MD 20852 which was published in the Federal Register on December 28, 2006, 71 FR 78214.

The meeting notice is changed to reflect the change in the name of the committee from “SBIR Topic 230 (Phases I & II)” to “SBIR, Synthesis Stable Isotope-Labeled Steroids as Internal Standards.” The meeting is closed to the public.